164 related articles for article (PubMed ID: 36718717)
41. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
42. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
43. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
44. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?
Hall NC; Kloos RT
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):793-805. PubMed ID: 17891243
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
46. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
[TBL] [Abstract][Full Text] [Related]
47. Interlesional 'flip-flop' between
Basu S; Kalshetty A; Fargose P
Natl Med J India; 2017; 30(1):48. PubMed ID: 28731009
[No Abstract] [Full Text] [Related]
48. PET imaging for thyroid cancers: Current status and future directions.
Giraudet AL; Taïeb D
Ann Endocrinol (Paris); 2017 Feb; 78(1):38-42. PubMed ID: 27989550
[TBL] [Abstract][Full Text] [Related]
49. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.
Salvatore B; Klain M; Nicolai E; D'Amico D; De Matteis G; Raddi M; Fonti R; Pellegrino T; Storto G; Cuocolo A; Pace L
Medicine (Baltimore); 2017 Oct; 96(42):e8344. PubMed ID: 29049252
[TBL] [Abstract][Full Text] [Related]
50. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
[TBL] [Abstract][Full Text] [Related]
51. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
53. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management.
Palmedo H; Bucerius J; Joe A; Strunk H; Hortling N; Meyka S; Roedel R; Wolff M; Wardelmann E; Biersack HJ; Jaeger U
J Nucl Med; 2006 Apr; 47(4):616-24. PubMed ID: 16595495
[TBL] [Abstract][Full Text] [Related]
54. [Diagnostics and treatment of differentiated thyroid cancer using nuclear medicine].
Morsing A; Bogsrud TV
Ugeskr Laeger; 2012 Jun; 174(26):1813-6. PubMed ID: 22735115
[TBL] [Abstract][Full Text] [Related]
55. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
56. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
Ranade R; Kand P; Basu S
Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
[TBL] [Abstract][Full Text] [Related]
57. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
58. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
Şahin E; Elboğa U
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
[TBL] [Abstract][Full Text] [Related]
59. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
60. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
